The Vital Role of Our Plasma Donors We could not create lifesaving medicines without the support of our plasma donors. Many plasma donations are needed to deliver plasma-derived therapies: 900 plasma donations to treat one person with alpha‑1 antitrypsin deficiency for one year 130 plasma donations to treat one person with primary immunodeficiency for one year 1,000 plasma donations to treat one person with hereditary angioedema (HAE) for one year 1,200 plasma donations to treat one person with severe haemophilia for one year Making Clinical Trials More Bear-able We are using interactive teddy bears called “Clinical Companions” with young participants in a clinical trial for hereditary angioedema (HAE). The bears, designed by Empath Labs, are equipped with an app to simulate medical procedures, helping children better understand and emotionally engage with their treatment, making the trial experience more comforting and less stressful. Partnering with the World Federation of Haemophilia During the 2024 calendar year, we donated >100 million international units (IUs) of coagulation factor therapy to the World Federation of Hemophilia (WFH) Humanitarian Aid Program. The Humanitarian Aid Program supports developing countries by providing them with product donations, education, and training to help countries improve inherited bleeding disorders care. The donation included therapies manufactured solely to be donated, which means it will have a longer shelf life and can help give patients consistent, reliable access to the treatments they need to prevent bleeding episodes. Three-year old Koylubaev, who lives with Haemophilia A, is pictured with his father at the National Center for Maternal and Child Health in Bishkek, Kyrgyzstan. 7 Limited Our Impact 2025 About CSL From our CEO Healthier Communities Science and Medicine Legacy Lifesaving Medicines
RkJQdWJsaXNoZXIy MjE2NDg3